Drug Profile
ATI 0917
Alternative Names: ATI-0917; FB 636Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Procter & Gamble
- Developer Arisyn Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action HIV replication inhibitors; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections in USA (PO)
- 24 Nov 2008 ATI 0917 is available for licensing (http://www.arisyn.com)
- 24 Nov 2008 Phase-I clinical trials for HIV infections in USA (PO)